Skip to main content

Table 3 Participants with plasma Phe ≤120 μmol/L, ≤360 μmol/L, or ≤ 600 μmol/L

From: Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study

  n Plasma Phe threshold, n (%)
≤120 μmol/L ≤360 μmol/L ≤600 μmol/L
Overalla 80 63 (78.7%) 64 (80.0%) 66 (82.5%)
Extension study
 Week 48 61 20 (32.8%) 28 (45.9%) 35 (57.4%)
 Week 96 49 17 (34.7%) 22 (44.9%) 30 (61.2%)
 Week 144 45 19 (42.4%) 25 (55.6%) 29 (64.4%)
 Week 192 39 13 (33.3%) 17 (43.6%) 23 (58.9%)
 Week 240 22 11 (50.0%) 13 (59.1%) 16 (72.7%)
 Week 264 19 5 (26.3%) 6 (31.6%) 8 (42.1%)
 Overall 68 57 (83.8%) 58 (85.2%) 59 (86.7%)
  1. All data from phase 2 studies are included. Sample size reflects participants with data available at study timepoint; study is ongoing
  2. Phe phenylalanine
  3. aAchievement of thresholds at any time during phase 2 study